Special Issue "Pharmacological Treatment for Gout"

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".

Deadline for manuscript submissions: 31 January 2024 | Viewed by 1401

Special Issue Editors

School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2006, Australia
Interests: clinical pharmacology; quality use of medicines; gout; pharmacogenomics; pharmacometrics; adherence
School of Pharmacy, University of Otago, P.O. Box 56, Dunedin 9056, New Zealand
Interests: allopurinol; colchicine; dose optimisation; chronic kidney disease; pharmacokinetics-pharmacodynamics

Special Issue Information

Dear Colleagues,

Gout is the most common form of inflammatory arthritis in men and has a prevalence of 1-4% globally. The incidence of gout is rising worldwide, including in both developing and, more dramatically, in developed nations. Gout is caused by the deposition of urate crystals. Treatment for acute gout flares focuses on alleviating the pain due to the intense inflammation and includes short courses of nonsteroidal anti-inflammatory drugs (NSAIDs), colchicine or glucocorticosteroids. Treatment of chronic gout centres on preventing gout flares and promoting the dissolution of tophi (urate deposits, if present) with urate-lowering therapy (ULT). The goal of ULT is to eliminate gout flares by reducing serum urate (SU) concentrations to ≤0.36 mmol/L (or <0.30 mmol/L if tophi are present). These targets are below the saturation point for SU (0.42 mmol/L), making the crystallisation and deposition of urate in the form of monosodium urate in joints less likely. Life-long treatment with ULT is recommended. Co-prescription of low-dose colchicine or NSAIDs for 6 months on initiation of ULT is recommended to prevent a paradoxical increase in gout flares related to sudden ULT-induced reduction in SU. Available ULTs include xanthine oxidoreductase inhibitors (allopurinol, febuxostat) and uricosuric agents (probenecid). Of these treatments, allopurinol is overwhelmingly the most common ULT prescribed. Despite the availability of effective and generally tolerable preventative treatments for gout, inadequate dosages and poor rates of persistence with ULT treatment regimens are prominent barriers to successful management. In the last decade, substantial efforts have been made to educate prescribers about titrating doses of ULT to reach target SU concentrations, rather than selecting a dose based on, and limited by, renal function, a historical approach dictated by concerns around toxicity. However, interventions to encourage dosing ULT to target SU concentrations have been very limited in their effect. Adherence to ULT was, on average, only 46.0% (95% confidence interval (CI) 40.8-51.2) in a recent meta-analysis. These data are consistent across the United States, the United Kingdom, Korea, Ireland, Israel and New Zealand.

Authors are invited to submit original and review articles on quantitative and qualitative research contributing to the understanding of the current state of gout treatment, to be published in this Special Issue of Pharmaceuticals. The proposed topics cover factors contributing to a suboptimal response to gout treatment, novel approaches to treating gout and interventions to improve gout management.

We look forward to your valuable contribution.

Dr. Sophie Stocker
Dr. Daniel F. B. Wright
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


11 pages, 601 KiB  
Gout Remission as a Goal of Urate-Lowering Therapy: A Critical Review
Pharmaceuticals 2023, 16(6), 779; https://doi.org/10.3390/ph16060779 - 23 May 2023
Viewed by 1079
Urate-lowering therapies for the management of gout lead to a reduction in serum urate levels, monosodium urate crystal deposition, and the clinical features of gout, including painful and disabling gout flares, chronic gouty arthritis, and tophi. Thus, disease remission is a potential goal [...] Read more.
Urate-lowering therapies for the management of gout lead to a reduction in serum urate levels, monosodium urate crystal deposition, and the clinical features of gout, including painful and disabling gout flares, chronic gouty arthritis, and tophi. Thus, disease remission is a potential goal of urate-lowering therapy. In 2016, preliminary gout remission criteria were developed by a large group of rheumatologists and researchers with expertise in gout. The preliminary gout remission criteria were defined as: serum urate < 0.36 mmol/L (6 mg/dL); an absence of gout flares; an absence of tophi; pain due to gout < 2 on a 0–10 scale; and a patient global assessment < 2 on a 0–10 scale over a 12-month period. In this critical review, we describe the development of the preliminary gout remission criteria, the properties of the preliminary gout remission criteria, and clinical studies of gout remission in people taking urate-lowering therapy. We also describe a future research agenda for gout remission. Full article
(This article belongs to the Special Issue Pharmacological Treatment for Gout)
Show Figures

Figure 1

Back to TopTop